Tolmar is a specialty pharmaceutical company with deep experience in urology, oncology, and endocrinology, including a strong position in the prostate cancer space. When the company began evaluating a potential U.S. license opportunity for Alpha Tau’s Alpha DaRT® therapy, the opportunity was strategically compelling but technically complex. As a non-radiopharmaceutical company, Tolmar needed expert support to assess the risks, requirements, and operational realities of bringing a novel alpha-radiation therapy into the U.S. urological cancer market.
Bracken was engaged to conduct focused due diligence across the areas that matter most in radiopharmaceutical development: manufacturing, supply chain, quality, regulatory strategy, licensing, treatment workflow, adoption readiness, and commercial feasibility.
What Needed to Be Understood
The opportunity required more than a traditional commercial review. Tolmar needed a clear, practical view of whether Alpha DaRT could be manufactured, supplied, licensed, delivered, and adopted in real-world U.S. clinical settings.
Radiopharmaceutical complexity sitting outside Tolmar’s core internal expertise
Manufacturing, isotope sourcing, vendor stability, and capacity risks that required specialized technical review
Quality, CMC, process flow, and historical incident considerations with potential implications for scale-up
NRC-related licensing, site readiness, staff training, and infrastructure requirements
Treatment workflow, referral pathways, and commercial adoption questions across the U.S. urology and oncology landscape
How Bracken Built the Diligence Strategy
Bracken assembled a risk-focused diligence workstream designed to help Tolmar move from strategic interest to informed decision-making.
Manufacturing & Supply Chain Assessment
Reviewed manufacturing processes, CMC and process flow, isotope sourcing, vendor stability, capacity, cost of goods, shipping risks, and site licensing considerations, helping Tolmar understand the operational requirements behind the therapy.
Quality & Vendor Diligence
Evaluated vendor readiness, historical quality incidents, supply chain resilience, and manufacturing dependencies through structured review, interviews, and direct assessment.
Site Feasibility Audits
Conducted in-person feasibility audits at both U.S. and international sites, including Jerusalem, to assess operational readiness, infrastructure needs, and implementation risks in real-world environments.
Regulatory & Licensing Readiness
Assessed NRC-related licensing considerations, treatment workflow requirements, staff training needs, infrastructure implications, and regulatory factors that could affect U.S. execution.
Commercial & Adoption-Readiness Support
Supported strategic and commercial diligence through KOL and payor interviews, health economic model outlining, referral pathway assessment, and additional client-requested analyses within Bracken consultant expertise.
Executive-Level Risk Reporting
Delivered structured diligence outputs, including a diligence request list, regular update calls, a midpoint checkpoint, final risk identification and validation, mitigation reporting, and executive-summary materials to support decision-making.
Clinical Adoption Readiness
Evaluated what it would actually take for Alpha DaRT to succeed beyond FDA approval, including target indications with the greatest unmet need, qualified treatment centers, staffing and facility readiness, treatment planning requirements, reimbursement potential, referral pathways, and expansion opportunities into future indications. The result was a practical roadmap for real-world clinical adoption rather than regulatory approval alone.
Measurable Outcomes
Radiopharmaceutical opportunities demand diligence that goes beyond market potential. Manufacturing, isotope sourcing, site readiness, licensing, workflow, and adoption risks can determine whether a promising therapy can realistically move from transaction to treatment.
Bracken helped Tolmar evaluate Alpha DaRT with the technical depth and strategic clarity needed to make an informed decision — connecting radiopharmaceutical expertise with commercial, regulatory, and operational execution.
Common Questions About Radiopharmaceutical Due Diligence
It goes well beyond a standard commercial review. For an alpha-radiation therapy like Alpha DaRT, diligence has to cover manufacturing and CMC, isotope sourcing, vendor stability and capacity, quality and historical incidents, NRC-related licensing, treatment workflow, site infrastructure, and real-world adoption. Bracken structured Tolmar’s diligence around exactly these dimensions so the company could weigh technical, regulatory, and commercial risk together rather than in isolation.
The hardest risks sit outside a traditional pharmaceutical company’s core expertise: securing a stable isotope supply, qualifying vendors with enough capacity, managing CMC and process-flow complexity, and meeting NRC licensing, staffing, and infrastructure requirements at each treatment site. Cost of goods and shipping logistics for short-lived isotopes add further pressure. Identifying these early is what turns a compelling opportunity into an executable one.
Delivering an alpha-radiation therapy in real-world settings requires NRC-related licensing, site readiness, trained staff, and appropriate infrastructure at each treatment center. Bracken assessed these considerations directly, including in-person site feasibility audits at U.S. and international sites, to clarify what U.S. implementation would actually demand. The goal was a practical view of workflow, training, and infrastructure needs, not just a regulatory checklist.
Approval alone does not guarantee uptake. Bracken evaluated the target indications with the greatest unmet need, which treatment centers are qualified, staffing and facility readiness, treatment planning requirements, reimbursement potential, and referral pathways, plus expansion into future indications. The result was a roadmap for real-world clinical adoption, showing what it would take for Alpha DaRT to reach patients after launch.
